Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.
2.

Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.

Malinin A, Pokov A, Spergling M, Defranco A, Schwartz K, Schwartz D, Mahmud E, Atar D, Serebruany V.

Thromb Res. 2007;119(3):277-84. Epub 2006 Mar 24.

PMID:
16563469
3.

Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation.

Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.

Thromb Haemost. 2009 Feb;101(2):333-9.

PMID:
19190818
4.

Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel.

Bouman HJ, Parlak E, van Werkum JW, Breet NJ, ten Cate H, Hackeng CM, ten Berg JM, Taubert D.

J Thromb Haemost. 2010 Mar;8(3):482-8. doi: 10.1111/j.1538-7836.2009.03733.x. Epub 2009 Dec 21.

5.

Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet Vasodilator-Stimulated Phosphoprotein flow cytometry.

von Beckerath N, Sibbing D, Jawansky S, Braun S, Morath T, Vogt W, Schömig A, Kastrati A.

Blood Coagul Fibrinolysis. 2010 Jan;21(1):46-52. doi: 10.1097/MBC.0b013e328332dbd4.

PMID:
19823079
6.

Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study.

Angiolillo DJ, Bernardo E, Palazuelos J, Desai B, Weisberg I, Alfonso F, Guzman LA, Hernández-Antolin R, Zenni MZ, Macaya C, Fernandez-Ortiz A, Bass TA.

Thromb Haemost. 2008 Jan;99(1):161-8. doi: 10.1160/TH07-09-0562.

PMID:
18217149
7.

Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel.

Malinin A, Pokov A, Swaim L, Kotob M, Serebruany V.

Methods Find Exp Clin Pharmacol. 2006 Jun;28(5):315-22.

PMID:
16845449
8.

Assessment of VerifyNow P2Y12 assay accuracy in evaluating clopidogrel-induced platelet inhibition.

Lordkipanidzé M, Pharand C, Nguyen TA, Schampaert E, Diodati JG.

Ther Drug Monit. 2008 Jun;30(3):372-8. doi: 10.1097/FTD.0b013e3181757c59.

PMID:
18520610
9.

How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.

Neubauer H, Lask S, Engelhardt A, Mügge A.

Thromb Haemost. 2008 Feb;99(2):357-62. doi: 10.1160/TH07-10-0624.

PMID:
18278186
10.

Evaluation of the platelet response to clopidogrel with light transmittance aggregometry: peak aggregation or late aggregation?

van Werkum JW, Kleibeuker M, Mieremet N, ten Berg JM, Hackeng CM.

J Thromb Haemost. 2007 Apr;5(4):884-6. No abstract available.

11.

A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis.

Jakubowski JA, Li YG, Small DS, Payne CD, Tomlin ME, Luo J, Winters KJ.

J Cardiovasc Pharmacol. 2010 Jul;56(1):29-37. doi: 10.1097/FJC.0b013e3181e0bab6.

PMID:
20386460
12.

A comparison of INNOVANCE® PFA P2Y and VerifyNow P2Y12 assay for the assessment of clopidogrel resistance in patients undergoing percutaneous coronary intervention.

Jang J, Lim J, Chang K, Kim Y, Kim M, Park HI, Kim J, Shin S.

J Clin Lab Anal. 2012 Jul;26(4):262-6. doi: 10.1002/jcla.21515.

PMID:
22811359
14.

The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration.

Jakubowski JA, Payne CD, Li YG, Brandt JT, Small DS, Farid NA, Salazar DE, Winters KJ.

Thromb Haemost. 2008 Feb;99(2):409-15. doi: 10.1160/TH07-09-0575.

PMID:
18278193
15.

VerifyNow and VASP phosphorylation assays give similar results for patients receiving clopidogrel, but they do not always correlate with platelet aggregation.

Bidet A, Jais C, Puymirat E, Coste P, Nurden A, Jakubowski J, Nurden P.

Platelets. 2010;21(2):94-100. doi: 10.3109/09537100903437206.

PMID:
20148735
16.

Common variation in the platelet receptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions.

Rudez G, Bouman HJ, van Werkum JW, Leebeek FW, Kruit A, Ruven HJ, ten Berg JM, de Maat MP, Hackeng CM.

Circ Cardiovasc Genet. 2009 Oct;2(5):515-21. doi: 10.1161/CIRCGENETICS.109.861799. Epub 2009 Jul 24.

17.

A comparison between the Plateletworks-assay and light transmittance aggregometry for monitoring the inhibitory effects of clopidogrel.

van Werkum JW, Kleibeuker M, Postma S, Bouman HJ, Elsenberg EH, ten Berg JM, Hackeng CM.

Int J Cardiol. 2010 Apr 1;140(1):123-6. doi: 10.1016/j.ijcard.2008.10.046. Epub 2008 Dec 16.

PMID:
19091430
18.

Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance.

Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, DeLao T, Bray PF, Kleiman NS.

J Am Coll Cardiol. 2006 Jan 3;47(1):27-33. Epub 2005 Dec 9.

19.

Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition.

Aradi D, Magyarlaki T, Tokés-Füzesi M, Rideg O, Vorobcsuk A, Komócsi A.

Platelets. 2010;21(7):563-70. doi: 10.3109/09537104.2010.494742.

PMID:
20642320
20.

Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition.

Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.

Heart. 2010 Feb;96(3):186-9. doi: 10.1136/hrt.2009.171488. Epub 2009 Aug 16.

PMID:
19687016

Supplemental Content

Support Center